//
sign in
Profile
by @danabra.mov
Profile
by @dansshadow.bsky.social
Profile
by @jimpick.com
AviHandle
by @danabra.mov
AviHandle
by @dansshadow.bsky.social
AviHandle
by @katherine.computer
EventsList
by @katherine.computer
ProfileHeader
by @dansshadow.bsky.social
ProfileHeader
by @danabra.mov
ProfileMedia
by @danabra.mov
ProfilePlays
by @danabra.mov
ProfilePosts
by @danabra.mov
ProfilePosts
by @dansshadow.bsky.social
ProfileReplies
by @danabra.mov
Record
by @atsui.org
Skircle
by @danabra.mov
StreamPlacePlaylist
by @katherine.computer
+ new component
Profile
Loading...



Loading...
Key points: A popular "hazard difference" estimator for averted outcomes is biased, but an unbiased one can be calculated from status-based aggregated data (knowing y/n vaccinated for those with and without the outcome). For avertible outcomes, this doesn't work; need to know dates of vaccination.
New paper: we argue that a promising approach for studying mpox vaccine effectiveness in Central Africa to incorporate mpox vaccination + testing data into existing cohort studies, especially those for HIV/STIs. www.thelancet.com/journals/ebi...
cisac.fsi.stanford.edu/content/cisa... In my new role at @stanfordcisac.bsky.social, I'm recruiting for a postdoc to define how benefits of risky research should be evaluated. w Tony Mills of @notredame.bsky.social . #philsci #biosecurity #scipolicy